Evaluation of COM503 Alone or with Zimberelimab for Safety and Dosage in Adults with Advanced Solid Tumors

What this Trial Is About

Researchers are evaluating the safety and dosing of COM503, given alone or with zimberelimab, in adults with advanced solid tumors. This first-in-human trial aims to find the maximum tolerated dose and recommended phase 2 dose of COM503 as both monotherapy and combined with zimberelimab. It focuses on advanced solid malignancies where standard treatments have failed or are unsuitable. The study includes several parts dose escalation of COM503 alone, dose escalation of COM503 combined with a fixed dose of zimberelimab, and dose expansion phases for both the monotherapy and combination therapy. Participants receive COM503 andor zimberelimab via intravenous infusion according to the assigned study part. During the trial, participants will undergo evaluations to monitor safety and tolerability from the first dose until 90 days after the last dose or the start of new anticancer therapy. Imaging with CT or MRI will assess tumor response. Researchers will track adverse effects, dosing limits, and overall safety profile over the study period. The trial is expected to last until November 2027.

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies